Get unlimited access to our best features
Subscribe now

US begins testing a universal flu vaccine

Summary by Ground News
Pfizer and its partner BioNTech plan to start clinical trials of pan-coronavirus vaccines in the second half of the year. The company said it wants to provide "durable variant protection," according to Reuters. Universal vaccines have been studied with limited success for years, but they are gaining renewed investment and research interest.
1 month ago·Washington, United States

News Articles

More Filters
All
Left
Center
Right
The Hill

US begins testing a universal flu vaccine

Story at a glance Flu vaccine efficacy varies from year to year due to a host of factors. In an effort to better protect against influenza, researchers developed a whole-virus vaccine. Previous tri…

1 month ago·Washington, United States
Read Full Article
Axios

Pfizer to begin testing universal coronavirus vaccines

Creating a vaccine that works against a variety of coronaviruses, including COVID-19, represents a holy grail.

1 month ago·Washington, United States
Read Full Article
Todo Noticias

BioNTech and Pfizer to Start Testing Universal Coronavirus Vaccine

They are studying injections that improve T cells and that further protect against possible serious diseases triggered by SARS-CoV-2.

1 month ago·Argentina
Read Full Article

The universal flu vaccine is a reality and has been developed by the U.S. UU.

The phase 1 trial will recruit up to 100 healthy subjects randomly distributed into three groups: intranasal, intramuscular, or placebo. In mice they were a success.

1 month ago
Read Full Article
biospace.com

BioNTech and Pfizer to Begin Testing Universal Coronavirus Vaccine

BioNTech announced it is partnering with Pfizer to begin testing a next-generation universal vaccine against coronaviruses, including SARS-CoV-2, the coronavirus that causes COVID-19.

1 month ago
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

100% of the sources are Center
The Hill
Axios
C 100%
See less detail